Eczema is a common inflammatory dermatitis characterized by dry, irritated skin with a recurring itchy rash involving erythema, edema, and pruritus ([@R2]; [@R12]; [@R18]; [@R20]). The most common type of eczema, atopic dermatitis (AD), affects 15%--30% of children and 2%--10% of adults ([@R5]; [@R7]; [@R12]; [@R20]). Typically, AD appears within the first 5 years of life ([@R2]), with approximately 70% of children outgrowing the condition by early adolescence ([@R20]); however, patients retain a lifelong predisposition for skin that is easily irritated.

AD presents as a condition with quiescent periods interrupted by periodic flare-ups. There are three clinical presentations of AD: subacute, acute, and chronic. Subacute eczema is characterized by dry, pruritic, scaly skin with erythematous papules and plaques ([@R2]; [@R20]). Acute eczema is characterized by red, pruritic papules and serous exudates ([@R20]). Secondary lesions can occur because of scratching, resulting in excoriations and crusted lesions. Chronic irritation and uncontrolled scratching can result in lichenification of the skin ([@R20]).

Pediatric skin differs from adult skin, having characteristics that may make it more prone to AD. The stratum corneum in infants is extremely thin and shows both increased exogenous water absorption rates and water desorption in the first year of life compared with adults, suggesting an inability to hold water ([@R17]). Over the first 1--4 years, the stratum corneum gains thickness and shows increased ability to hold water, with infant and toddler skin actually having higher water content than adult skin, despite lower natural moisturizing factor levels. However, the smaller and less dense corneocytes and keratinocytes, thinner total epidermis, inability to maintain hydration homeostasis, and higher ratio of surface area to volume in the skin of young children all reflect skin with compromised barrier integrity ([@R9]; [@R17]). This compromised barrier results in water loss and xerotic skin, which is easily irritated and difficult to heal. To overcome the itch--scratch cycle evident in AD, the skin needs to be adequately hydrated, and the itch needs to be controlled to allow the skin to heal ([@R20]).

Current European and U.S. guidelines recommend the daily application of emollient moisturizers for both the prevention and treatment of AD ([@R6]; [@R11]; [@R18]). Emollient therapy can improve hydration, prevent transepidermal water loss (TEWL; [@R5]), and relieve itching ([@R7]). Topical corticosteroids are the primary prescription product used to control flare-ups of AD, with short-term oral steroids (up to 1 week) used to treat major exacerbations. However, long-term use of topical or oral steroids is not recommended for the treatment of AD, particularly in children, because of the risk for cutaneous side effects, rebound flare-ups, suppression of growth rate, and reduced bone density ([@R11]; [@R18]). In addition, reports indicate that approximately 50% of parents request steroid-sparing medications for their children with moderate-to-severe eczema because of concerns about adverse events ([@R13]; [@R16]).

Development of steroid-free, over-the-counter (OTC) skin care products that can support the barrier and help manage bothersome symptoms is a major goal for eczema therapy. We have developed two new OTC products for the management and treatment of AD. The first is a Body Cream designed for daily use to maintain hydration of the skin, support skin barrier function, and reduce TEWL. An Instant Therapy cream has been designed to specifically treat acute AD flare-ups, calming the skin and supporting hydration and barrier repair. Both products contain colloidal oatmeal, licochalcone, ceramide 3, and castor oil. In addition, Instant Therapy contains menthoxypropanediol, a novel cooling agent to calm itch and provide a cooling sensation.

Here, we report on two controlled clinical studies conducted to test the efficacy and tolerability of the Body Cream and Instant Therapy in infants and children with AD.

METHODS
=======

Overview of Clinical Studies
----------------------------

Two single-center, 2-week clinical studies were conducted to assess the efficacy and tolerability of two emollient creams---one designed for daily moisturization (Eucerin Eczema Relief Body Crème: Body Cream) and the other for acute therapy of AD lesions (Eucerin Eczema Relief Instant Therapy cream: Instant Therapy). Both formulations were developed by Beiersdorf, Inc. (Wilton, Connecticut), for the treatment of AD.

Patient Enrollment and Eligibility
----------------------------------

In Study 1, male and female infants, toddlers, and children aged 3 months to 12 years with a history of atopic skin disease were enrolled at a clinical research center in Colorado Springs, CO. Study 1 subjects with one or more active atopic skin sites of mild-to-moderate severity were analyzed as an active eczema subgroup. In Study 2, conducted in Carrollton, TX, all subjects had at least one active atopic skin site of mild-to-moderate intensity. The age range was the same as for Study 1. All parents/guardians of subjects signed an informed consent form approved by the Institutional Review Board and a disclosure agreement as required by the Health Insurance Portability and Accountability Act (HIPAA).

Study Design
------------

No products were applied to the treatment test areas for ≥2 days before the treatment test period. In Study 1, Body Cream was applied to both legs (knee to ankle; all subjects) and to the designated active eczema lesion and surrounding unaffected skin (subgroup only) twice daily for 14 days. In Study 2, Instant Therapy was applied to designated lesions twice daily for 14 days (all subjects) in the morning and evening after cleansing. Assessments were conducted on Days 7 and 14.

Efficacy and Tolerability Assessments
-------------------------------------

### Corneometer measurements

Corneometer CM 825 (Courage and Khazaka, Germany) electrical capacitance measurements were made at the outer aspect of both legs and the active lesion and their adjacent sites to measure product hydration effects on the skin surface; increases in average measurements relative to baseline indicated improved skin hydration.

### Skin irritation assessments

A 4-point scale (0 = *none*, 3 = *severe*) was used by clinicians to grade erythema, edema, and tactile roughness of the outer legs. Parents graded itching and burning/stinging of legs and active lesions using the same scale.

### Product assessment questionnaire

Parents/guardians completed a product evaluation regarding skin condition and each test material's efficacy and characteristics at Day 14.

### Imaging procedures

Digital photographs were taken of designated active lesions and the surrounding, unaffected skin using a Nikon D7000 digital SLR camera.

### Atopic Dermatitis Severity Index (Study 2 Only)

Designated active lesions were evaluated using the Atopic Dermatitis Severity Index (ADSI; [@R23]), assessing the following components of the target lesion(s): erythema, pruritus, exudation, excoriation, and lichenification. Each component was evaluated according to a 4-point grading system (0 = *none*, 3 = *severe*) with a total ADSI score of 0--15.

### Tolerability assessments

Global tolerability of the test material for each subject was evaluated by a clinician according to a 4-point scale (1 = *excellent*, 4 = *poor*). Adverse events were recorded.

Statistical Analysis
--------------------

The per-protocol population was used for the efficacy and tolerance testing. For skin irritation assessments and ADSI, statistical change from baseline was calculated using Wilcoxon's signed-rank test. Statistical change in corneometer measurements used a paired *t* test. For the product evaluation questionnaire, a binomial (sign) test was used to determine if the proportion of the combined designated favorable responses was equal to the combined designated negative responses for each question. Statistical analyses were performed using SAS software version 9.30 series (SAS Institute, Inc., Cary, NC).

RESULTS
=======

Subject Demographics
--------------------

Sixty-four infants and children aged 3--151 months with a history of AD completed Study 1; 26 subjects had active lesions at enrollment and were included in the subgroup assessments. In Study 2, 29 infants and children aged 3--147 months with mild-to-moderate active AD completed the study. Demographic information is summarized in Table [1](#T1){ref-type="table"}.

###### 

Summary Demographics: Per-Protocol Populations for Body Cream Moisturizing Therapy (Study 1) and Instant Therapy Cream (Study 2)
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Study 1: Body Cream Assessment
------------------------------

### Skin hydration

Body Cream significantly improved stratum corneum moisture content of the lower legs after 7 and 14 days of twice-daily application compared with baseline (*p* ≤ .001; Figure [1](#F1){ref-type="fig"}A). Corneometer values were significantly increased by 33.6% at Day 7 and 40.8% at Day 14. Application of Body Cream for 2 weeks also significantly improved corneometer measurements in the active lesion (91.6%) and surrounding skin (33.4%) compared with baseline (*p* \< .001; Figure [1](#F1){ref-type="fig"}B).

![Improvement in skin hydration with Body Cream. Study 1: Corneometry measures after 14 days of twice-daily application. (A) Skin hydration levels were measured on the outer sides of each lower leg and averaged; *N* = 64. \**p* \< .001 versus baseline. (B) Skin hydration levels of active lesion and surrounding skin in subgroup; *N* = 29. An increase in measurement indicates an improvement in skin hydration. \**p* \< .001 versus baseline.](jdn-7-17-g002){#F1}

### Skin irritation

Clinical grading of skin irritation indicated that Body Cream significantly reduced erythema and tactile roughness after 2 weeks. Tactile roughness scores were reduced by 81.7% at Day 7 and by 95% at Day 14 (*p* \< .001; Figure [2](#F2){ref-type="fig"}). Body Cream significantly reduced erythema by 70% after 2 weeks of treatment (*p* = .016; Figure [2](#F2){ref-type="fig"}). Mean itching scores decreased by 63.6% at Day 7 and 84.8% by Day 14 (*p* \< .001). Burning/stinging sensations were also reduced by 57.1% at Day 7 and by 85.7% at Day 14 (Figure [2](#F2){ref-type="fig"}). No edema was present at baseline; thus, there was no change for this assessment.

![Skin irritation assessment. Tactile roughness, erythema, itching, and burning/stinging were graded on a 4-point scale (0 = *none*, 3 = *severe*); *N* = 64. \**p* \< .001 versus baseline, ^†^*p* \< .05 versus baseline.](jdn-7-17-g003){#F2}

Symptoms of itching and burning/stinging also improved significantly in subjects with active lesions. The active subgroup baseline itch scores were notably higher than scores for the legs (1.42 vs. 0.52); the lesions showed significant reductions in itch at Days 7 (35.1% reduction, *p* = .031) and 14 (54.1% reduction, *p* = .003). Burning and stinging scores in the active subgroup decreased by 78.6% (*p* = .006).

Body Cream visibly improved the appearance of skin affected by AD after 14 days of twice-daily treatment (Figure [3](#F3){ref-type="fig"}).

![Improvement in appearance of active lesions after 2 weeks of Body Cream treatment. Improvements seen at Day 14 in erythema, dryness, and scaling on the face.](jdn-7-17-g004){#F3}

### Product evaluation questionnaire

The questionnaire analysis showed that a statistically significant proportion of parents indicated agreement (strongly agree or agree) with statements supporting the efficacy and tolerability of Body Cream (Figure [4](#F4){ref-type="fig"}). Overall, 94% of parents/guardians confirmed that the product effectively moisturized their child's skin, 94% stated that it did not irritate skin, 91% reported that it soothed skin, 88% thought that it protected their child's skin from dryness, and 100% agreed that it was gentle enough to use every day.

![Product assessment questionnaire of Body Cream. Parents completed a questionnaire on the qualities of Body Cream at Day 14. Percentages show the combined responses that agreed or strongly agreed with the statements; \<5% disagreed with any statement, and the remainder neither agreed nor disagreed. The proportion of all responses indicating agreement was statistically significant.](jdn-7-17-g005){#F4}

### Tolerability

All subjects were graded as experiencing either "good" or "excellent" tolerability to Body Cream at Day 14. One subject experienced a mild transient erythematous rash on the lower legs; however, the subject continued daily application of the test product to the site, and the rash resolved after several days of treatment.

Study 2: Instant Therapy Assessment
-----------------------------------

### Skin hydration

Instant Therapy significantly improved hydration levels of active lesions by 70.1% (*p* \< .001) and surrounding skin by 29.3% (*p* = .001) at Day 14 (Figure [5](#F5){ref-type="fig"}). Active lesion hydration with Instant Therapy was significantly greater compared with the surrounding skin (*p* = .04), although the moisture level of the surrounding skin was within normal range.

![Improvement in skin hydration with Instant Therapy. Study 2: Corneometry results for active lesions and surrounding skin; *N* = 29. An increase in measurement indicates an improvement in skin hydration. \**p* \< .05 versus baseline, ^†^*p* ≤ .001 versus baseline.](jdn-7-17-g006){#F5}

### ADSI clinical grading

Instant Therapy application significantly improved AD severity, decreasing total ADSI scores by 41.8% and 58.4% at Days 7 and 14, respectively (*p* \< .001; Figure [6](#F6){ref-type="fig"}). Improvement in overall score was observed in 93.1% of subjects at Week 2. Treatment with Instant Therapy significantly improved the individual symptoms of AD, with the greatest improvements observed for pruritus (64.9%), erythema (54.0%), and lichenification (57.1%) at Day 14 (*p* \< .001) and excoriation (73.6%) at Day 7 (*p* = .004; Figure [6](#F6){ref-type="fig"}). The visible improvement in the appearance of active lesions and the surrounding skin after 2 weeks of Instant Therapy can be seen in Figure [7](#F7){ref-type="fig"}; before and after photographs show examples of improvements in erythema, excoriation, lichenification, and lesion intensity after 2 weeks of treatment.

![Improvement in Atopic Dermatitis Severity Index (ADSI) scores in Study 2. Individual ADSI symptoms were graded on a scale of 0 (*none*) to 3 (*severe*); sum provides total ADSI (maximum of 15); *N* = 29. \**p* \< .001 versus baseline, ^†^*p* \< .05 versus baseline.](jdn-7-17-g007){#F6}

![Improvement in active lesions after 2 weeks of Instant Therapy treatment. Improvements seen at Day 14 in erythema and exudation of the lower lateral leg (A), lichenification of the lower leg (B), and erythema and scaling on the back of the neck (C).](jdn-7-17-g008){#F7}

### Product evaluation questionnaire

A statistically significant proportion of parents indicated agreement (strongly agree or agree) with statements that Instant Therapy was effectively able to moisturize their child's itchy skin (93%), was able to calm skin (83%), works immediately to soothe skin (76%), relieves itchy skin (86%), protects against dryness (79%), reduces redness (90%), and was gentle enough to use every day (90%; Figure [8](#F8){ref-type="fig"}).

![Product assessment questionnaire of Instant Therapy. Parents completed a questionnaire on the qualities of Instant Therapy at Day 14. Percentages show the combined responses that agreed or strongly agreed with the statements; \<5% disagreed with any statement, and the remainder neither agreed nor disagreed. The proportion of all responses indicating agreement was statistically significant.](jdn-7-17-g009){#F8}

### Tolerability

All subjects experienced either "good" or "excellent" tolerability to the Instant Therapy after 2 weeks of twice-daily treatment. One subject was reported as experiencing eczema, which resolved after 5 days. The subject continued product use and completed the study without additional medication. The investigator judged the event as having an unknown relationship to the test material.

DISCUSSION
==========

AD is a highly prevalent skin condition in infants and children. Current guidelines for maintenance therapy of atopic skin recommend daily application of emollient therapy, whereas corticosteroids are typically used to control flare-ups ([@R6]; [@R11]; [@R18]). However, approximately 50% of parents were reported to request nonsteroidal medications to treat their children's moderate-to-severe eczema ([@R13]; [@R16]). Parents' reluctance to use topical steroids suggests that many children do not receive their prescribed steroid treatment until the condition has escalated ([@R13]; [@R16]). Hence, there is a need for steroid-free moisturizing skin care treatments that are safe and well tolerated in young children with compromised skin barriers.

Both the Body Cream and Instant Therapy were well tolerated in children as young as 3 months. Only one adverse event, a mild erythematous rash, was considered possibly related to treatment with the Body Cream; however, it was transient and resolved while treatment continued. No adverse events were related to treatment with the Instant Therapy. None of the subjects discontinued the study because of adverse events or for any other reason.

Daily hydration and protection of the skin may help to reduce the frequency of AD flares. Body Cream and Instant Therapy significantly improved the hydration of skin, particularly that of active lesions, as shown by the corneometry results. Similar studies in adults have shown that these products significantly improved barrier function, as evidenced by a decrease in TEWL ([@R24]).

In addition, the daily application of the Body Cream significantly improved the symptoms of AD, including erythema, tactile roughness, and itching.

The efficacy and tolerability shown by the Body Cream and Instant Therapy were observed without the use of concomitant prescription therapy. Although there are other OTC preparations available in the United States for the treatment of AD, very few have been studied in pediatric subjects, and several of those studies permitted the continuation of topical steroid treatment throughout the treatment period ([@R4]; [@R21]; [@R22]). Allowing concomitant treatment makes it difficult to assess the true efficacy of the emollient formulation.

Symptoms of AD can have a dramatically negative impact on quality of life. Constant itching and discomfort can disrupt sleep as well as daytime work, school, and leisure activities ([@R15]). Itching can also exacerbate the existing inflammation, preventing the skin from healing. Both Body Cream and Instant Therapy significantly improved the symptoms of AD, most notably itching. Parents confirmed the efficacy of both products, with more than 90% agreeing that the products effectively moisturized their child's itchy skin, calmed and soothed itch, protected against dryness, reduced redness, and were gentle enough to use every day. In addition, the skin showed overall visible improvements, which can be seen in Figures 3 and 7.

The efficacy and tolerability of the Body Cream and Instant Therapy are because of their formulations. Both product formulations are acidic, supporting the optimal pH of healthy skin and counteracting pH disturbances observed in atopic patients. The acidic milieu of the stratum corneum suppresses *Staphylococcus aureus* bacterial growth and is necessary for the functioning of enzymes that drive lipid synthesis and maturation and the desquamation process ([@R18]). The formulas also contain ingredients known to soothe skin and enhance barrier repair, including colloidal oatmeal, ceramide 3, licochalcone, and castor seed oil. Oatmeal, a skin protectant active for eczema approved by the US Food and Drug Administration, contains several dermatologically active constituents with moisturizing, soothing, anti-inflammatory, barrier protective, and antioxidant properties. Oatmeal has been shown to have clinical efficacy as adjunctive therapy in reducing symptoms of AD, including itch ([@R10]). Ceramides are one of three stratum corneum lipid constituents of the skin barrier, deficiencies of which have been linked to AD ([@R14]). In the Eucerin formulations, ceramide 3 is an important constituent that combats the skin barrier defect, preventing TEWL and dryness. Licochalcone has been shown to have anti-inflammatory effects on the skin that may reduce skin irritation, erythema, and itching ([@R3]). Castor seed oil contains natural emollients that deeply penetrate the skin, moisturizing the skin and reducing TEWL and dryness. The Instant Therapy cream contains twice the ceramide content of the Body Cream as well as menthoxypropanediol, a cooling agent that provides rapid relief of itching and burning sensations upon contact ([@R1]). Both formulations calm and soothe itch and other symptoms of AD and support barrier repair.

CONCLUSIONS
===========

AD causes great discomfort for many children as they experience constant itch and subsequent scratching, inflamed lesions, and lichenification. Symptoms have a considerable negative impact on the quality of life for both children and parents. Providing parents with OTC options that are effective and well tolerated will help maintain the adequate hydration and protection needed for children with AD. The Eucerin Body Crème and Instant Therapy products have been specifically formulated to provide hydration and support barrier repair as well as to reduce symptoms of AD, allowing affected skin to heal. The studies reported here indicate that these products were effective and well tolerated in infants and children with AD as young as 3 months without the use of concomitant therapy. These formulations have also been tested in adults, with similar improvements in hydration and symptoms of AD ([@R24]). These products provide effective OTC treatments for eczema that are gentle enough for daily use in infants and children.
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